☆ 4.7 Letter

Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy

KIDNEY INTERNATIONAL (2021)

Related references

Note: Only part of the references are listed.

Review Urology & Nephrology

Rituximab in Membranous Nephropathy

Philipp Gauckler et al.

Summary: Membranous nephropathy is the most common cause of primary nephrotic syndrome among adults, and rituximab is now considered a first-line treatment option due to its favorable safety profile. However, questions remain about the optimal use of rituximab, and further research is needed to address these uncertainties.

KIDNEY INTERNATIONAL REPORTS (2021)

Add to Collection

Article Transplantation